Tag: Viking Therapeutics

Viking Therapeutics has successfully completed patient enrollment for its pivotal VANQUISH-1 Phase 3 clinical trial ahead of schedule, marking a ...

The competitive landscape for anti-obesity medications has been jolted by a significant development from Viking Therapeutics. The biopharmaceutical company announced ...

Viking Therapeutics has achieved a significant advancement in its obesity treatment program, completing patient enrollment for its pivotal Phase 3 ...

Shares of Viking Therapeutics reached their highest point in ten months during Wednesday's trading session, continuing a significant upward trend. ...

Shares of Viking Therapeutics experienced significant upward momentum this week, fueled by renewed takeover speculation and a positive analyst update. ...

The biotech sector's attention is firmly fixed on Viking Therapeutics as the company prepares for a featured presentation at the ...

Viking Therapeutics has captured significant market attention following the release of impressive clinical trial results for its obesity treatment candidate ...

Viking Therapeutics is generating significant attention in the biotech sector with new clinical findings for its experimental weight-loss treatment, VK2735. ...

Investors in Viking Therapeutics were met with sobering financial results for the third quarter of 2025, as the biotechnology firm ...

Viking Therapeutics is experiencing significant positive momentum this October, driven by substantial progress in its obesity treatment candidate VK2735. The ...